Is Trientine on the market?

Trientine (Trientine) is an important drug mainly used to treat Wilson's disease, a genetic disorder caused by excessive accumulation of copper in the body. Trientine helps remove excess copper by binding to copper ions in the body, thereby mitigating damage to the liver and other organs. Trientine becomes an effective alternative for patients who are intolerant to penicillamine, another drug used to treat Wilson's disease.

The hydrochloride form of trientine is called trientine hydrochloride, which received marketing approval in November 1985 under the trade name Syprine. With the in-depth research on this drug, it was found that it has good safety and effectiveness in clinical application, so it is widely recommended for the treatment of Wilson's disease. Although penicillamine has a long history and rich experience with use, trientine is gradually gaining attention due to its unique mechanism of action and is recommended by some experts as a first-line treatment option.

In addition, trientine tetrahydrochloride (trade nameCuprior) was approved for medical use by the European Union in 2017, aiming to provide a treatment option for adults, adolescents and children over five years old who are intolerant to D-penicillamine therapy. This approval marks the further expansion of trientine’s use worldwide. Following this, trientine dihydrochloride (trade name Cufence) also received similar approval in 2019, further strengthening trientine's position in the treatment of Wilson's disease.

It is worth mentioning that,In November 2023, according to the franchise policy of Hainan Boao Lecheng International Medical Tourism Pilot Zone, Quenting was launched in the region through specific channels. This measure reflects China's emphasis on the introduction of new drugs and innovation in medical services, further enhances the treatment options available to patients, and promotes the rational allocation of medical resources.

Reference materials:https://en.wikipedia.org/wiki/Triethylenetetramine